Kiox Pharmaceuticals ApS: Financial statements 2024
CVR: 42886866
Source: annual report 2024, Danish Business Authority
01/01/2024 – 31/12/2024
Kiox Pharmaceuticals ApS (CVR 42886866) has filed annual accounts for 2024. In 2024, the company reported a gross profit of DKK -411,764 and a net result of DKK -1,841,030 compared with DKK -968,993 the year before. Equity in the 2024 report amounted to DKK 235,170. The solvency ratio was 30%.
- Gross Profit
- DKK -411,764
- Profit/Loss
- DKK -1,841,030
- Equity
- DKK 235,170
- Total Assets
- DKK 784,380
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2024 | - | -412 t. | -1.8 mio. | 235 t. | - |
| 2023 | - | 412 t. | -969 t. | -64 t. | - |
| 2022 | - | -3 t. | -3 t. | 37 t. | - |
Official annual report
Screen every Danish company
Combine filters on financials, industry, geography, property and risk, and instantly see which companies match.
Try company screeningEvents in 2024
Kiox Pharmaceuticals ApS has published its annual report for 2023. Gross profit came to DKK 412,113, and the net result was DKK -968,993.
As of February 5, 2024, Tim Dehli Carstensen is registered as director of Kiox Pharmaceuticals ApS.
As of February 5, 2024, Titi14 HOLDING ApS is registered as an owner of Kiox Pharmaceuticals ApS with an ownership share of 20%.
About Kiox Pharmaceuticals ApS
Kiox Pharmaceuticals ApS is a Danish company of the type Anpartsselskab based in Snekkersten, founded in 2021. The company is registered under the industry Andre liberale, videnskabelige og tekniske tjenesteydelser i.a.n.. The management consists of Mikkel Walmar and Tim Dehli Carstensen. The board consists of Mikkel Walmar (chair), Inge Tarnow and Lars Hellerung Christiansen. The company is owned by HELLERUNG ApS, Titi14 HOLDING ApS and 26c Holding ApS. In 2025, the company reported a gross profit of DKK 120,473 and a net result of DKK -639,537 compared with DKK -1,841,030 the year before. Equity in the 2025 report amounted to DKK -404,366.